THERAPEUTIC SLTNS INTL - TSOI STOCK NEWS

Therapeutic Solutions International (TSOI) reported successful treatment of 15 patients using the JadiCell™ adult stem cell product under the Right to Try Law. Notably, 12 COVID-19 patients showed profound recovery, and retired Navy SEALs exhibited significant improvement in biomarkers linked to Chronic Traumatic Encephalopathy (CTE). The company is advancing towards Phase III clinical trials for JadiCells, focusing on patient safety and treatment effectiveness amid ongoing COVID-19 challenges.

Therapeutic Solutions International has received a Notice of Allowance from the United States Patent and Trademark Office for its patent on QuadraMune®, a nutraceutical aimed at enhancing the immune system by inhibiting the indolamine 2,3 deoxygenase (IDO) pathway. This is a pioneering patent for a nutraceutical supplement in this area. The company aims to tap into the $15.2 billion checkpoint inhibitor market. Several ingredients in QuadraMune have shown potential anti-COVID effects, validated by independent universities after patent filing.

Therapeutic Solutions International, Inc. (OTC Markets: TSOI) has initiated pilot batch production of JadiCells, its FDA-cleared umbilical cord stem cell product, set to enter Phase III clinical trials for COVID-19. The company successfully reproduced manufacturing protocols under US patent #9,803,176 B2 for various indications. This milestone aims to reduce production costs and enhance accessibility for healthcare providers. Enhanced internal manufacturing aligns with the anticipated demand driven by the Right to Try Law and Emergency Use Authorization.

Therapeutic Solutions International, Inc. (OTC Markets: TSOI) announced lab data showing that exosomes from JadiCells™, the Company's Phase III COVID-19 therapy candidate, can inhibit neutrophil extracellular trap production. These traps are linked to inflammation in conditions such as COVID-19 and cancer. The findings support a patent application and suggest potential for new treatments for inflammation-related diseases. Dr. James Veltmeyer highlighted the rapid translation of this discovery into applications, while Timothy Dixon emphasized the opportunity for First in Class approaches for big pharma partnerships.

Therapeutic Solutions International (TSOI) highlighted their nutraceutical QuadraMune™, designed to enhance immunity against COVID-19. The company pointed to strong independent research backing its ingredients, such as Pterostilbene and Thymoquinone, which exhibit antiviral properties against SARS-CoV-2 and aid immune response. CEO Timothy Dixon emphasized the growing demand for natural therapies alongside new COVID-19 variants. QuadraMune™ stands out in the market due to its scientific validation, potentially positioning TSOI favorably for future developments in the immunomodulation space.

Therapeutic Solutions International (OTC Markets: TSOI) announced promising data and a new patent for a cellular therapy aimed at reducing lung injury and promoting lung regeneration. The research shows that combining T regulatory cells from umbilical cord blood with JadiCells effectively suppresses lung damage in experimental models. The findings suggest a molecular mechanism involving the GITR pathway that enhances therapy efficacy. The company is preparing to launch an FDA Phase III trial for COVID-19 patients while exploring additional molecular switches to improve stem cell activity.

Therapeutic Solutions International (OTC Markets: TSOI) announced promising new data indicating that its nutraceutical, QuadraMune™, enhances the effects of ivermectin in animal models mimicking COVID-19. The study revealed that while ivermectin had a minimal impact on lung inflammation, combining it with QuadraMune™ significantly improved outcomes by stimulating natural killer (NK) cells. The company is exploring combination trials between these treatments and emphasizes the findings' potential clinical implications.

Therapeutic Solutions International (TSOI) announced successful treatment of a Navy SEAL Veteran suffering from Chronic Traumatic Encephalopathy (CTE) using JadiCell adult stem cells. The treatment involved two injections with no adverse events reported. The company is committed to clinical trials, having received Phase III clearance for COVID-19 ARDS and planning a Phase I/II trial for CTE. The initiative provides pro bono access to military personnel. The CEO expressed pride in supporting veterans amid rising suicide rates, emphasizing the urgent need for new therapeutic strategies.

Therapeutic Solutions International (TSOI) announced on September 10, 2021, the engagement of Venvalo Group to manage regulatory and strategic aspects of its FDA-cleared Phase III clinical trial for JadiCells, aimed at treating advanced COVID-19. Principal Investigator Dr. Camillo Ricordi praised the collaboration, citing prior successful trials with a 100% survival rate for patients under 85. CEO Timothy Dixon expressed excitement about leveraging expertise for effective clinical translation and developing an Emergency Use Application.